Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc. Common Shares (NY: CYBN )

8.260 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
39 40 Next >
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
Via Investor Brand Network
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated... 
Via Benzinga
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From January 17, 2023
Via Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
The "Multi-Bagger" Portfolio Update: Week Ending January 27
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 but many of them could possibly bounce back with major returns in 2023. We track the performance of a basket of 10 such... 
Via Talk Markets
Largest Psychedelic Stocks +1.2% This Week; Now +16.1% YTD
We track the 6 largest psychedelic stocks that research the treatment of mental illnesses based on the use of one or more psychedelic substances - weekly and YTD results. 
Via Talk Markets
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
Via Investor Brand Network
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
Cybin to Host Virtual R&D Day on February 28, 2023
From Cybin Inc.
Via Business Wire
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 23, 2023
Via Benzinga
Largest Psychedelic Stocks +3% This Week; Now +15% YTD
Our Psychedelic Drug Stocks Index tracks the six largest psychedelic stocks, by market capitalization, that research the treatment of mental illnesses based on the use of one or more of 10 different... 
Via Talk Markets
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 19, 2023
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin Touts Promising Results From Sponsored Kernel Flow Study Measuring Psychedelic Effects On The Brain
Cybin Inc. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study
Via Investor Brand Network
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January. 
Via Benzinga
Psychedelics Companies Join The Race To Develop Much-Needed Anxiety Treatment
Life sciences biotech company Cybin Inc. (NYSE: CYBN) announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its... 
Via Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
A "Multi-Bagger" Portfolio For 2023 - Introduction
I am optimistic that the market will perform better in 2023 so I've put together a basket of 10 stocks that could well realize multi-bagger returns this year. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From January 13, 2023
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.